Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Study Phase : IND Enabling
Recipient : Jemincare
Deal Size : Undisclosed
Deal Type : Agreement
Details : According to the agreement, Orion has the right to develop and commercialise the JMKX000623, NaV 1.8 blocker asset in its territory. Orion will be fully responsible for its own development and commercialisation costs.
Brand Name : JMKX000623
Molecule Type : Small molecule
Upfront Cash : $15.8 million
May 06, 2022
Lead Product(s) : JMKX000623
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Recipient : Jemincare
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Bispecific Antibody
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Alligator Bioscience
Deal Size : $552.8 million
Deal Type : Collaboration
Details : Under the agreement, Alligator Bioscience will employ its proprietary phage display libraries and RUBY™ bispecific platform to develop immuno-oncology product candidates based on design criteria identified by Orion.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Bispecific Antibody
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Alligator Bioscience
Deal Size : $552.8 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
